Summary Safety Review - GARDASIL (Quadrivalent Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) - Assessing General Safety with a Focus on Autoimmune and Cardiovascular Diseases

The safety of all vaccines, including Gardasil, is under continuous monitoring by Health Canada and the Public Health Agency of Canada. The safety of Gardasil was reassessed as part of this monitoring and when cases of side effects after vaccination with Gardasil were reported in early 2015. These side effects included diseases where the body's own defence system attacks itself (autoimmune diseases), such as rheumatoid arthritis and multiple sclerosis, and diseases affecting the heart and blood vessels (cardiovascular diseases), such as low blood pressure and blood clots.

Data and Resources

Additional Info

Field	Value
Last Updated	April 17, 2026, 17:34 (UTC)
Created	April 17, 2026, 17:34 (UTC)
criticality_level	[]
geographic_scope	[]
open_canada_collection	publication
open_canada_date_published	2017-05-18 00:00:00
open_canada_keywords	{"fr": ["Examen sommaire de l'innocuité", "Gadolinium", "évaluation", "risque", "accumulation de gadolinium", "cerveau", "système cérébral et nerveux", "effets secondaires neurologiques"], "en": ["Summary Safety Review", "GARDASIL", "all vaccines", "side-effects after vaccination", "Quadrivalent Human Papillomavirus", "Recombinant Vaccine", "assessing general safety", "Autoimmune", "Cardiovascular Diseases", "body's own-defence-system attacks-itself", "autoimmune diseases", "diseases affecting", "heart-and-blood-vessels", "cardiovascular diseases"]}
open_canada_subject	["health_and_safety"]
sensitivity_level	unrestricted
title_fr	Résumé de l'examen de l'innocuité - GARDASIL (vaccin recombinant quadrivalent contre le virus du papillome humain [types 6, 11, 16 et 18]) - Évaluation de l'innocuité générale et du risque de maladies auto immunes et cardiovasculaire
update_frequency	as_needed